Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission. More: Astellas bags orphan drug status for AML drug Source: News
read moreCost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing
read moreThe European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy. More: EC OKs Adcetris for CD30-positive cutaneous T-cell lymphoma Source: News
read moreThe commercial life for Novartis’ Arzerra outside the U.S. is coming to an end. On Monday, Novartis partner Genmab said the Swiss drugmaker would pull the chronic lymphocytic leukemia product from all ex-U.S. markets and set up compassionate use programs
read moreFederal investigators have been looking into possible price fixing at top generic drugmakers for years, and on Friday, a top Department of Justice official signaled what his agency might do next. More: Feds may sue generic drugmakers to recover damages:
read moreAfter the cytomegalovirus vaccine Astellas licensed from Vical failed in a kidney transplant phase 2 study, hope of the shot rested on a phase 3 in hematopoietic stem cell transplant recipients. But that hope has just been shattered too. More:
read more© 1994 - 2026 B.M. Pharmaceuticals